Introduction
Synaptotagmins (syts) are a family of membrane proteins featured by an N-terminal transmembrane domain (type I membrane topology), two C-terminal tandem C2 domains (C2A and C2B), which are responsible for binding calcium and phospholipids, and a short conserved Cterminal sequence, which may be crucial for docking to the plasma membrane and correct folding of the C2B domain [1] [2] [3] [4] . Syts and SNARE [soluble N-ethylmaleimeide-sensitive factor (NSF) attachment protein (SNAP) receptor] proteins are likely to represent the minimal protein complement for Ca 2+ -triggered exocytosis [5] . In vertebrates, 16 isoforms of syt have been identified [6] , some of which appear to function as Ca 2+ sensors that couple Ca 2+ to membrane fusion in vivo and in vitro [7, 8] . The most abundant isoform, syt I, appears to function as a Ca
2+
sensor that triggers the rapid exocytosis of synaptic vesicles from neurons, but the functions of the remaining syt isoforms are ill-defined. Syts are known to be evolutionarily and functionally well conserved genes and thought to be derived from common ancestral genes. Distinct variants generated by alternative splicing have been reported, including transmembrane exon skipping and syt VII splice variants that differentially regulate synaptic vesicle recycling [9] [10] [11] [12] .
The partial sequence of a putative chr415 syt gene, so-called by Craxton [13] , has been suggested to be a human orthologue of mouse syt XIV in the human genome [14] . In the present report, we have completed the sequence of chr415 syt gene and found by cloning, sequencing and chromosomal localization that this gene is different from syt XIV and encodes a novel protein that shows a high amino acid identity with that of syt XIV. We have coined this new gene as synaptotagmin XIV-derived protein (sytdep) as it is phylogenetically related to syt XIV. In addition,
we have found that human polymorphonuclear neutrophils (PMNs) express high levels of sytdep, but not syt XIV.
Materials and methods
Cell culture and neutrophil isolation. The human acute myeloid leukemia HL-60 cell line was grown in RPMI-1640 mediun supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 24 μg/ml gentamicin at 37 ºC in a humidified atmosphere of air/CO 2 (19/1). Neutrophil differentiation of HL-60 cells was induced by adding 1.3 % (v/v) dimethyl sulfoxide (DMSO) as previously described [15] . The human astrooligodendroglioma (grade II/III) GOS-3 cell line was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 24 μg/ml gentamicin at 37 ºC in a humidified atmosphere of air/CO 2 (19/1).
Neutrophils were obtained from fresh human peripheral blood by dextran sedimentation and centrifugation on Ficoll-Hypaque (Pharmacia LKB Biotechnology, Uppsala, Sweden), followed by hypotonic lysis of residual erythrocytes as previously described [16] , and the final cell preparation contained more than 99 % neutrophils as assessed by Wright-Giemsa staining. Postnuclear neutrophil extracts were prepared and processed for Western blotting as previously described [17] .
Nucleic acid isolation and reverse transcription-polymerase chain reaction (RT-PCR).
Both genomic DNA and total RNA were purified from the different cell types used in this work using the DNAzol genomic DNA isolation reagent and the TRIZOL reagent (Gibco BRL, Gaithersburg, MD), respectively. RNA preparations were carefully checked by gel electrophoresis and found to be free of DNA contamination. Total RNA (5 μg), primed with oligo-dT, was reverse-transcribed into cDNA at 37ºC for 2 h using the first-strand cDNA synthesis kit (Amersham Biosciences, for 30 min at room temperature with constant rotation. Then, these biotinylated lysates were precleared with protein A-Sepharose as previously described [19] . Affinity-purified rabbit polyclonal antibody raised against the C2B domain of syt XIV fused to GST [14] , and P3X63 myeloma culture supernatant (a kind gift of Dr. F. Sánchez-Madrid, Hospital de La Princesa, Madrid, Spain), used as a negative control, were coupled to protein A-Sepharose beads (Amersham Biosciences) by incubation for 2 h at 4ºC with constant rotation. These beads were pelleted, washed twice with lysis buffer, and incubated with the supernatant from the preclearing step for 2 h at 4ºC with constant rotation. Sepharose beads were then pelleted and washed 5 times with lysis buffer.
Then, 20 μl SDS sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol) were added, and samples were subjected to SDS-15% PAGE under reducing conditions and immunoblotted [20] . 
Results and discussion

Identification and molecular characterization of sytdep
A putative syt gene, named chr415 syt (GenBank/EMBL accession number, AJ303368), was identified and partially sequenced in a previous study by Craxton [13] . We cloned and sequenced chr415 syt in human neutrophils and found its identity to chr415 syt, with only one nucleotide difference (Fig. 1A) . Recently, this gene was assigned to syt XIV [14] by sequence comparison.
However, we have found evidences that questioned this assumption. First, comparison of the partial nucleotide and amino acid sequence of chr415 syt with that corresponding to syt XIV showed differences both in DNA and protein sequences ( Fig. 1 ), although amino acid sequence comparison of chr415 syt with the six isoforms of syt XIV indicated that the protein encoded by this gene showed a strong homology with isoform 2 of syt XIV (Fig. 1B) . Secondly, we found that human neutrophils expressed chr415 syt, but not syt XIV (data not shown), using RT-PCR and a wide array of PCR primers covering the whole sequences of syt XIV and chr415 syt. On these grounds, we asked whether these two sequences could correspond to two different genes. Using the BLASTn program we analyzed the chromosome location of both genes, aligning all known syt XIV isoforms and chr415 syt sequence versus the full human genome. Surprisingly, two distinct gene loci for syt XIV and chr415 syt were found in the human chromosomal positions 1q32.2 and 4q13.2, respectively.
In order to characterize the nucleotide sequences of both the genomic locus and transcript corresponding to the gene defined by the partial chr415 syt sequence, we carried out a BLASTn analysis of the partial cDNA sequence known of chr415 syt in the human chromosome 4 region (positions from 8932396 to 8929693), which led to a prediction of 2584 bp for the full-length chr415 syt cDNA ( Fig. 2A) . By RT-PCR assays we found a cDNA sequence that contained a single ORF encoding a protein of 188 amino acids with a deduced molecular mass of 21.435 kDa ( Fig.   2A ). These results extended and completed the partial nucleotide sequence of chr415 syt. We also found one nucleotide difference at position 479, leading to a Thr-Met change at residue 97 ( Fig.   2A ). We coined the name sytdep (synaptotagmin XIV-derived protein) for this new gene (GenBank accession no. AY954513). The predicted full-length sytdep cDNA contained a 189-bp 5'-untranslated region (5'-UTR), a 564-bp ORF, and a 1831-bp 3'-UTR ( Fig. 2A) . The rather long length of the 3' untranslated sequence might be similar to that highly conserved of rat and human syt I gene, arguing for conserved functions in non-coding regions. The sytdep cDNA showed high identity with three clones of human chromosome 4 (GenBank accession nos. AC096727,
BC041902, and AJ617629).
The amino acid sequence of human sytdep showed 75% identity to synaptotagmin XIV. The primary sequence of sytdep showed a 57% identity to the human syt XIV-related protein (strep14, a.k.a. syt XVI), and 20-24%, 10-19% and 12% identity to other syt isoforms, syt-like proteins (slps) and slp homologue lacking C2 domain protein (slac2), respectively. On the other hand, the Nterminal region (24 amino acids) of sytdep did not show any significant homology with any known protein domain. A physiological role for the N-terminal region of Syt in neutransmission has been recently reported [21] . This might suggest a specific role for sytdep that remains to be elucidated.
Unlike most synaptotagmin XIV isoforms (Fig. 1B) (Fig. 2, A and B) , which could be sufficient for a putative transmembrane domain, but the location of these regions in the C2B domain make this option particularly implausible as C2B domains do not act as transmembrane domains. Three potential N-glycosilation sites (Asn-XaaSer/Thr; 60-62, 141-143, and 158-160), one potential O-glycosilation (Thr-Xaa-Ser, 39-41) site, and a number of potential Ser, Thr and Tyr phosphorilation sites (12/2/2) were found in the deduced amino acid sequence of sytdep ( Fig. 2A) . No potential N-myristoylation or prenylation sites were detected, but three Cys residues at the N-terminal domain might be fatty-acylated as it happens in some syts [26] .
Genomic structures of human syt XIV and sytdep
The gene structures of human syt XIV and sytdep were determined by database searching and PCR approaches. The human syt XIV and sytdep genes were mapped to chromosome 1 and 4, spanning 226,054 and 2,584 bp, respectively. Syt XIV gene consisted of 10 exons with 9 introns of various lengths, whereas sytdep gene showed a unique exon (Fig. 3) . The Syt XIV exon 4 encoded the transmembrane domain, and the C2A and C2B domains were encoded by exon 7 and exons 8-10, respectively. Syt XIV exon 3 is not translated as it occurs with other human syt genes containing 5' non-coding exons [13] . domains (exons 7 and 9, respectively) give rise to the distinct isoforms. Table 2 shows the distinct exon and intron compositions as well as the exon-intron junctions of the human syt XIV gene, containing the highly conserved sequences for RNA splicing in higher eukaryotes, namely GT at the 5' splice site (donor site) and AG at the 3' splice site (acceptor site) [27] , except exons 7 and 9 that show in addition GC and TG as intron 5'-and 3'-splice donor and acceptor sites.
Using BLAST search from the human genome database and DNA sequencing we mapped sytdep locus in chromosome 4 containing the exons 1, 2, 3, 4, 8 and 10 of syt XIV with no introns (Fig. 3) . Due to the high similarity between sytdep and syt XIV, it could be envisaged that the human sytdep gene might originate from a syt XIV transcript derived of chromosome 1, which was retrotranslocated to a genomic region of chromosome 4. Thus, as shown in Fig. 3 , the sytdep genomic locus could result from a fusion of exons 1, 2, 3, 4, 8 and 10 of syt XIV gene.
Interestingly, the mouse genome did not contain sytdep by database searching. In addition,
we were unable to identify sytdep in mouse brain cDNA by RT-PCR (data not shown). Thus, the above putative retrotranslocation leading to sytdep apparently occurred in human, but not in mouse.
Sytdep expression in human neutrophils
Because sytdep and synaptotagmin XIV isoforms showed a high degree of homology, we next asked whether these genes could be differentially expressed. We designed specific primers for the distinct syt XIV isoforms and sytdep, and carried out RT-PCR experiments with different pairs of primers (Table 1 and Fig. 4 ), in peripheral blood human neutrophils, human leukemia HL-60 cells, neutrophil-differentiating-HL60 cells, and human astro-oligodendroglioma GOS-3 cell line.
The HL-60 cell line has been widely used as a cell culture model to study different molecular aspects of human neutrophils, as it acquires many biochemical and functional characteristics of mature neutrophils following treatment with DMSO for 4 days [15] . As shown in Fig. 4 , sytdep was highly expressed in mature peripheral blood neutrophils, and resulted upregulated during neutrophil differentiation of HL-60 cells. However, no syt XIV expression was detected. GOS-3 cells expressed both sytdep and syt XIV isoform. Cloning and sequencing of the syt XIV amplified band indicated that this amplicon corresponded to syt XIV isoform 2.
We next investigated whether the sytdep transcript was translated into protein in human neutrophils where we found a high sytdep mRNA expression. Due to the high identity (84%)
between the C2B domains of syt XIV and sytdep, we assumed that a polyclonal antibody against the C2B domain of syt XIV could detect the C2B-containing sytdep protein. By immunoprecipitating biotinylated cell protein extracts with the above polyclonal antibody, we observed an immunoreactive band of ~27 kDa in the neutrophil extract (Fig. 5A) Because we have found that SNARE proteins are involved in human neutrophil exocytosis [17, 19, 28] , and syts have been reported to interact with SNARE proteins [5, [29] [30] [31] , it is tempting to suggest a putative role for sytdep in the secretory response of human neutrophils where sytdep mRNA is particularly highly expressed. The unique major functional domain present in sytdep is the C2B domain, which has been involved in binding to other C2B domains, accessory proteins independent of divalent cations and phospholipids, as well as in exocytosis [32] [33] [34] . The polybasic Lys-rich region of C2B domain has been implicated in the binding to phosphatidylinositol (4,5)-bisphosphate in the absence of Ca 2+ [35, 36] . On these grounds, it could be envisaged that the C2B domain of the new gene sytdep might be involved in membrane trafficking in human neutrophils via binding to phosphoinositides. The expression of sytdep in human neutrophils might increase the number of exocytosis-related genes, including SNARE proteins [17, 19, 28] , expressed in human neutrophils. Herrero-Turrión, M.J.
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